Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F25%3A10500147" target="_blank" >RIV/00064165:_____/25:10500147 - isvavai.cz</a>
Alternative codes found
RIV/61988987:17110/25:A2603DOA RIV/00216208:11110/25:10500147
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Ftr6nu9DJV" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Ftr6nu9DJV</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/bloodadvances.2024014695" target="_blank" >10.1182/bloodadvances.2024014695</a>

Result language
angličtina
Original language name
Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes
Original language description
The POLARIX study demonstrated a sustainable improvement in progression-free survival (PFS) with Pola-R-CHP (polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone) vs R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), with a similar tolerability profile in previously untreated diffuse large B-cell lymphoma (DLBCL). This report provides additional details regarding peripheral neuropathy (PN) events from both a physician and patient perspective. Clinician- and patient-reported outcomes (ClinROs and PROs, respectively) similarly reported no increase in the incidence rate or severity of PN events in patients treated with Pola-R-CHP compared with R-CHOP.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)